ClinicalTrials.gg
Not yet recruitingNCT07211100Updated Oct 7, 2025

Evaluation of the Effectiveness of a Mobile Application Developed for Hemodialysis Patients.

An interventional study of Mobile Health Application in End-Stage Renal Disease Requiring Haemodialysis and Mobile Application, sponsored by Saglik Bilimleri Universitesi. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-07.

Sponsored by Saglik Bilimleri Universitesi · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Pain by Saglik Bilimleri Universitesi — 6 open to participants now, 8 under way, none of them phase 3. Pain · Saglik Bilimleri Universitesi.

Planned enrollment
17th of 32
72 · median 73
Started
2025
with 6 others
No phase
31 of 33
5 open now
Registered
28th of 33
by date

Among the 33 studies in Pain by Saglik Bilimleri Universitesi, this one is the 17th largest by planned enrollment of the 32 interventional ones that give a count, is one of 7 that started in 2025, is one of 31 with no phase, and was the 28th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

6 of the 33 studies in Pain by Saglik Bilimleri Universitesi are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Pain by Saglik Bilimleri Universitesi, or all of them as a file.
02

Study summary

This study aims to evaluate the effectiveness of a mobile health application developed for adult patients undergoing hemodialysis treatment. The mobile application includes modules on adherence to medication, diet, and fluid restrictions, symptom management (fatigue, pain, itching), nutrition guidance, exercise recommendations, and motivational content. It also features reminder notifications, an "Ask the Expert" module, and personal symptom tracking.

The research will be conducted as a single-center, single-blind, randomized controlled experimental study. Participants will be assigned to intervention and control groups using block randomization. The intervention group will receive the mobile application, while the control group will receive standard care. Assessments will be carried out at baseline (T0), 1st month (T1), and 2nd month (T2).

The measurement tools to be used include the End-Stage Renal Disease Adherence Questionnaire (ESRD-AQ), Post-Dialysis Fatigue Scale, 5-D Itch Scale, Visual Analog Scale (VAS) for pain, and the Mobile Application Usability Scale. In addition, clinical parameters such as serum potassium, phosphorus, and albumin will be evaluated.

A total of 72 patients (36 intervention, 36 control) will be included in the study. This study aims to assess the impact of a mobile health application on treatment adherence, symptom management, and clinical parameters among hemodialysis patients, and to develop a digital health model that can be integrated into nursing care.

Read the detailed description

Chronic kidney disease is a major global public health problem, and most patients with end-stage renal disease (ESRD) depend on hemodialysis to survive. Patients undergoing hemodialysis often experience difficulties with treatment adherence, challenges related to dietary and fluid restrictions, as well as common symptoms such as fatigue, pain, and itching. These problems negatively affect their quality of life. Previous studies have reported that more than half of hemodialysis patients demonstrate poor treatment adherence, which is associated with increased mortality. Therefore, innovative and technology-based approaches are needed to improve adherence and reduce symptom burden.

In recent years, mobile health (mHealth) applications have been increasingly used in the management of chronic diseases. Such applications enable patients to monitor their health more closely, improve medication and dietary adherence, and receive support for symptom management. However, most existing studies in the literature have focused on only one dimension of adherence (such as medication or diet) and have not comprehensively evaluated symptom management together with biochemical parameters.

This study aims to investigate the effect of a newly developed mobile health application, created by the research team, on treatment adherence, symptom management (fatigue, pain, itching), and clinical parameters (serum potassium, phosphorus, albumin) among hemodialysis patients. The study will be conducted as a single-center, single-blind, randomized controlled trial including a total of 72 patients (36 intervention, 36 control). Participants will be assigned to groups using block randomization. The intervention group will receive the mobile application, while the control group will continue with standard care.

The mobile application has been specifically designed and developed by the research team to meet the needs of hemodialysis patients. It consists of modules on treatment adherence (medication, diet, fluid restriction, dialysis attendance), symptom management (fatigue, itching, pain), nutrition guidance, exercise recommendations, reminder notifications, a question-answer section with experts, and personal monitoring. The aim is to improve patients' self-care abilities and reduce their symptom burden.

Data will be collected at baseline (T0), 1st month (T1), and 2nd month (T2). Measurement tools include the End-Stage Renal Disease Adherence Questionnaire (ESRD-AQ), Post-Dialysis Fatigue Scale, 5-D Itch Scale, Visual Analog Scale (VAS) for pain, and the Mobile Application Usability Scale. In addition, laboratory parameters such as serum potassium, phosphorus, and albumin will be evaluated.

At the end of the study, scientific evidence will be obtained regarding whether the mobile health application developed by the research team is effective in improving treatment adherence, alleviating symptoms, and enhancing clinical outcomes in hemodialysis patients. The findings are expected to provide a model for integrating digital health applications into nursing care and to contribute to the healthcare system.

03

Conditions studied

  • End-Stage Renal Disease Requiring Haemodialysis
  • Mobile Application

Keywords

  • hemodialiysis
  • mobile application
  • mobil health
  • pain
  • fatigue
  • itching
  • nursingcare
  • adaptation
  • esrd
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years.
  • Diagnosed with end-stage renal disease (ESRD).
  • Receiving maintenance hemodialysis treatment for at least 3 months.
  • Able to use a smartphone and willing to install the mobile health application.
  • Voluntarily agreeing to participate in the study and providing written .

Exclusion criteria

Exclusion Criteria:

  • Patients with cognitive impairment, severe psychiatric disorders, or communication barriers that may interfere with participation.
  • Patients with visual or hearing impairments that prevent the use of the mobile application.
  • Patients who have undergone kidney transplantation or are scheduled for transplantation within the study period.
  • Patients with serious comorbid conditions requiring hospitalization (e.g., advanced cancer, severe heart failure).
  • Participation in another interventional clinical trial within the past 3 months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Arm 1 - Intervention Arm

    Participants assigned to this arm will receive the mobile health application developed by the research team. The application includes modules on treatment adherence (medication, diet, fluid restriction, dialysis attendance), symptom management (fatigue, pain, itching), nutrition guidance, exercise recommendations, reminder notifications, expert Q\&A, and personal tracking.

    Behavioral: Mobile Health Application

  • No intervention
    Arm 2 - Control Arm

    Participants in this group will receive standard hemodialysis care without the mobile application. Standard care includes routine clinical follow-up, medical treatment, and nursing care provided at the dialysis center.

Interventions

  • BehavioralMobile Health Application

    A mobile health application developed by the research team to support hemodialysis patients. The application includes modules on treatment adherence (medication, diet, fluid restriction, dialysis attendance), symptom management (fatigue, pain, itching), nutrition guidance, exercise recommendations, reminder notifications, expert Q\&A, and personal tracking. The aim is to improve adherence to treatment, reduce symptom burden, and support patient self-care.

06

What researchers measure

Primary outcomes

  1. Change in Treatment Adherence Score

    Treatment adherence will be assessed using the End-Stage Renal Disease Adherence Questionnaire (ESRD-AQ). Higher scores indicate better adherence. The intervention group will use the mobile health application, while the control group will receive standard care.

    Time frame: Baseline (T0), 1 month (T1), and 2 months (T2).

  2. Change in Symptom Burden

    ymptom burden will be evaluated using the Edmonton Symptom Assessment Scale (ESAS), which covers multiple symptoms such as fatigue, itching, pain, sleep disturbance, and other common hemodialysis-related complaints. Higher scores reflect higher symptom severity.

    Time frame: Baseline (T0), 1st month (T1), and 2nd month (T2).

Secondary outcomes

  1. Mobile Application Usability

    Measured by the Mobile Application Usability Scale among intervention group participants.

    Time frame: At the 2nd month and after.

07

Study locations

1 site
  • Gumushane State Hospital
    Gümüşhane, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared because this study is a doctoral thesis project, and data use is restricted to the research team in accordance with ethics committee approval.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2025; primary completion for Dec 2025, 1 month later.

Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 1 month is below that.

Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2025
First posted
Oct 7, 2025
StartEst.
Nov 2025
Primary completionEst.
Dec 2025
CompletionEst.
Feb 2026
Last update
Oct 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07211100
Collaborators
Gümüşhane Universıty
Responsible party
İlknur Palaz (Doctoral Student and lecturer, Saglik Bilimleri Universitesi) — Principal investigator
First posted
Oct 7, 2025
Start date
Nov 2025 (estimated)
Primary completion
Dec 2025 (estimated)
Completion
Feb 2026 (estimated)
Last update
Oct 7, 2025

Study contacts

İlknur PALAZ, PHD STUDENT
Contact
ilknurpalaz@gumushane.edu.tr
+905324511583

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion